Combination of palbociclib with adjuvant endocrine therapy for treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer: An experience at two cancer centers in Saudi Arabia

The addition of palbociclib (a cyclin-dependent kinase 4/6 inhibitor) to endocrine therapy (ET) has been shown to significantly improve progression-free survival (PFS) and overall survival (OS) among patients with hormone receptor-positive (HR(+)) advanced breast cancer. The current study presents t...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Foheidi, Meteb H., Albeshri, Asem Mohammed, Moamenkahan, Safwan Noor, Abdullah, Abdulmajid Mohammed, Abualola, Muhannad Sadaqa, Alharbi, Muath Hamed, Refa, Ahmed A., Bayer, Ali M., Shaheen, Ahmed Y., Aga, Syed Sameer, Khan, Muhammad Anwar, Al-Mansour, Mubarak M., Ibrahim, Ezzeldin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204325/
https://www.ncbi.nlm.nih.gov/pubmed/35747598
http://dx.doi.org/10.3892/mco.2022.2552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204325/
https://www.ncbi.nlm.nih.gov/pubmed/35747598
http://dx.doi.org/10.3892/mco.2022.2552

Ejemplares similares